
|Videos|April 20, 2021
CAR T Therapy and Durable Responses in MCL
Author(s)Frederick L. Locke, MD
Frederick Locke, MD, discusses treatment options for patients with mantle cell lymphoma and the use of CAR T-cell therapy in clinics.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves Subcutaneous Amivantamab for EGFR-Mutated NSCLC Indications
2
Enfortumab Vedotin Plus Pembrolizumab Improves Survival in MIBC
3
FDA Grants Regular Approval to Rucaparib for BRCA-Mutated mCRPC
4
Long-Term ECHO Data Support Concurrent Acalabrutinib/BR in MCL
5





































